নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

pfizer as - noretisteron - tablett - 0.35 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

pfizer as - misoprostol - tablett - 0.2 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

pfizer as - noretisteron / etinyløstradiol - tablett

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sedana medical ab - isofluran - væske til inhalasjonsdamp - 100 % v/v

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

vitabalans oy - paracetamol / kodeinfosfathemihydrat - tablett - 500 mg / 30 mg

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. bortsett fra i nydiagnostisert kronisk fase kml, det er ingen kontrollerte studier som viser en klinisk nytte eller økt overlevelse for disse sykdommer. .

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

ge healthcare ltd - krom (51cr) edetat - injeksjonsvæske, oppløsning - 3.7 mbq/ ml

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

warner chilcott uk ltd. - testosteron - seksuelle dysfunksjoner, psykologisk - sex hormoner og modulatorer av genital systemet, - intrinsa er indisert for behandling av hypoactive seksuell lyst lidelse (hsdd) i bilateralt oophorectomised og hysterectomised (kirurgisk indusert overgangsalder) kvinner mottar samtidig estrogen terapi.

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

morningside healthcare (malta) limited - amantadinhydroklorid - kapsel, hard - 100 mg

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

dendreon uk ltd - autologous perifere blod mononukleære celler inkludert minst 50 millioner autologous cd54 + celler aktivert med prostatic sure fosfatase granulocytt-macrophage koloni-stimulerende faktor - prostata neoplasmer - andre immunstimulerende midler - provenge er indisert for behandling av asymptomatisk eller minimalt symptomatisk metastatisk (ikke-visceral) castratresistent prostatakreft hos mannlige voksne der kjemoterapi ennå ikke er klinisk indikert.